A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
A phase 1/2 trial of Ivonescimab, Cadonilimab, Sintilimab in hepatocellular carcinoma, run by Akeso, now recruiting.
Overview
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) is a phase 1/2 interventional study registered as NCT06530251 by Akeso, with 280 participants planned, started 2024-09-24 and due to reach its primary completion in 2026-06. Interventions recorded: AK112, Cadonilimab, AK127, AK130, Sintilimab Injection. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Shares Cadonilimab, Ivonescimab, Akeso, Hepatocellular carcinoma.
- TrialA Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Shares Cadonilimab, Akeso, Hepatocellular carcinoma.
- TrialAn Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Shares Cadonilimab, Ivonescimab, Akeso.
- TrialA Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat
Shares Cadonilimab, Akeso, Hepatocellular carcinoma.
- TrialAK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
Shares Cadonilimab, Ivonescimab, Akeso.
- TrialA Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Shares Cadonilimab, Akeso.
- TrialA Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Part
Shares Sintilimab, Hepatocellular carcinoma.
- TrialA Study of Ivonescimab in First-Line ES-SCLC
Shares Cadonilimab, Ivonescimab, Akeso.